NCT00511004View on ClinicalTrials.gov

Effect of Albendazole Dose on Treatment of Lymphatic Filariasis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Lymphatic Filariasis
Interventions
DRUG

Albendazole

Comparing 400 mg to 800 mg dose

DRUG

Diethylcarbamazine

Providing diethylcarbamazine more frequently in combination with albendazole

Trial Locations (1)

Unknown

Filariasis Chemotherapy Unit (FCU), T.D. Medical Hospital, Alleppey, Kerala

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00511004 - Effect of Albendazole Dose on Treatment of Lymphatic Filariasis | Biotech Hunter | Biotech Hunter